Paroxysmal Nocturnal Hemoglobinuria (PNH) Clinical Trial
Official title:
A Multi-center, Randomized, Parallel, Open-label Clinical Phase II Study, to Evaluate the Efficacy and Safety of MY008211A in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients With Signs of Active Hemolysis
The main purpose of this study is to evaluate the efficacy of MY008211A in adult patients with PNH, showing signs of active hemolysis.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | December 2025 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Male and female participants = 18 years of age and BMI = 18.0 kg/m2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size = 10%. - Mean hemoglobin level <100 g/L. - LDH > 1.5 x Upper Limit of Normal (ULN). - Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment. If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given. Exclusion Criteria: - Patients with reticulocytes <100x10^9/L; platelets <30x10^9/L; neutrophils <0.5x10^9/L. - Were using a complement inhibitor before the first administration of MY008211A tablets or had discontinued a previous complement inhibitor for less than five half-lives or 120 days, whichever was the longest. - History of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus. - Known or suspected hereditary complement deficiency. - Previous bone marrow or hematopoietic stem cell transplantation. - Previous splenectomy. - A history of malignancy within 5 years before screening, except cured local basal cell carcinoma of the skin and carcinoma in situ of the cervix. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Wuhan Createrna Science and Technology Co., Ltd |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of subjects with an increase in hemoglobin concentration = 20 g/L from baseline among subjects who do not receive RBC transfusion after 4 weeks of dosing | Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of = 20 g/L assessed , in the absence of red blood cell transfusions | Day 70 | |
Secondary | The proportion of patients with an increase in hemoglobin = 20 g/L from baseline among those without RBC transfusion | The proportion of patients with an increase in hemoglobin = 20 g/L from baseline among those without RBC transfusion | Day14, 21, 28, 42, 56 | |
Secondary | The proportion of patients with hemoglobin = 120 g/L among those without RBC transfusion | The proportion of patients with hemoglobin = 120 g/L among those without RBC transfusion | Day14, 21, 28, 42, 56 and 70 | |
Secondary | Change in hemoglobin concentration from baseline in patients without RBC transfusion | Change in hemoglobin concentration from baseline in patients without RBC transfusion | Day14, 21, 28, 42, 56 and 70 | |
Secondary | Change in LDH level from baseline | Change in LDH level from baseline | Day7, 14, 21, 28, 42, 56 and 70 | |
Secondary | The proportion of patients with hemolysis controlled | The proportion of patients with hemolysis controlled (defined as LDH < 1.5 ULN) | Day7, 14, 21, 28, 42, 56 and 70 | |
Secondary | Change in reticulocyte count from baseline in patients without RBC transfusion | Change in reticulocyte count from baseline in patients without RBC transfusion | Day7, 14, 21, 28, 42, 56 and 70 | |
Secondary | Change in indirect bilirubin level from baseline | Change in indirect bilirubin level from baseline | Day7, 14, 21, 28, 42, 56 and 70 | |
Secondary | The proportion of patients without RBC transfusion | The proportion of patients without RBC transfusion | Day14, 21, 28, 42, 56 and 70 | |
Secondary | Change in the average weekly amount of RBC transfused during the efficacy observation period | Change in the average weekly amount of RBC transfused during the efficacy observation period compared with that pre-dose | Day70 | |
Secondary | Change From Baseline in FACIT-Fatigue Questionnaire | Change from baseline in FACIT-Fatigue scores. The FACIT-Fatigue is a 13-item questionnaire with support for its validity and reliability in PNH that assesses patient self-reported fatigue and its impact on daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F Scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best. | Day7, 14, 21, 28, 42, 56 and 70 | |
Secondary | Changes from baseline in alternative complement pathway activity | Alternative complement pathway activity measured by the WIESLAB® kit. | Day14, 28, 56 and 70 | |
Secondary | Change in the amount of fragment Bb of CFB in plasma from baseline | Bb fragment cleaved by factor B of complement. | Day14, 28, 56 and 70 | |
Secondary | Change in the level of PNH RBC clones from baseline in patients without RBC transfusion. | Change from baseline in the level of PNH red cell clones. | Day70 | |
Secondary | Incidence of Adverse Events (AEs) between Day 1 and Day 70 | Adverse Events (AEs) | Day 70 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00004143 -
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
|
Phase 2 | |
Terminated |
NCT05116787 -
BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy
|
Phase 2 | |
Recruiting |
NCT06294301 -
A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants
|
Phase 1 | |
Completed |
NCT03472885 -
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab
|
Phase 2 | |
Completed |
NCT03946748 -
Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Enrolling by invitation |
NCT03427060 -
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
|
Phase 2 | |
Completed |
NCT03078582 -
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
|
Phase 2 | |
Completed |
NCT03053102 -
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Not yet recruiting |
NCT06312644 -
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
|
||
Completed |
NCT03588026 -
Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576
|
Phase 3 | |
Completed |
NCT03056040 -
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
|
Phase 3 | |
Completed |
NCT00145613 -
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00587054 -
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
|
Phase 2 | |
Recruiting |
NCT05876312 -
Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
|
Phase 1 | |
Completed |
NCT04820530 -
Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
|
Phase 3 | |
Terminated |
NCT03225287 -
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
|
Phase 2 | |
Completed |
NCT04558918 -
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
|
Phase 3 | |
Completed |
NCT02352493 -
A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
|
Phase 1/Phase 2 | |
Recruiting |
NCT04901936 -
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Phase 2 | |
Completed |
NCT02264639 -
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
|
Phase 1 |